| Diffuse large B-cell lymphoma (DLBCL): early patient management and emerging treatment options P Vodicka, P Klener, M Trneny OncoTargets and Therapy 15, 1481, 2022 | 22 | 2022 |
| Polatuzumab vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B‐cell lymphoma in the real world P Vodicka, K Benesova, A Janikova, V Prochazka, D Belada, H Mocikova, ... European Journal of Haematology 109 (2), 162-165, 2022 | 17 | 2022 |
| Idelalisib plus rituximab versus ibrutinib in the treatment of relapsed/refractory chronic lymphocytic leukaemia: A real‐world analysis from the Chronic Lymphocytic Leukemia … M Špaček, L Smolej, M Šimkovič, L Nekvindová, Z Křístková, Y Brychtová, ... British Journal of Haematology 202 (1), 40-47, 2023 | 7 | 2023 |
| Expression of molecules of the Wnt pathway and of E‑cadherin in the etiopathogenesis of human thymomas P Vodicka, L Krskova, I Odintsov, L Krizova, E Sedlackova, J Schutzner, ... Oncology Letters 19 (3), 2413-2421, 2020 | 7 | 2020 |
| Risk of Central Nervous System Vs. Systemic Relapse in Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: What Should We Focus on? M Klanova, S Hricko, M Masar, D Salek, P Vodicka, N Kopalova, ... Blood 142, 4479, 2023 | | 2023 |
| Do the Control Cohorts of Phase III Randomized Trials Reflect the Real-World Results of DLBCL Patients? P Vodicka, A Janikova, D Belada, H Mocikova, V Prochazka, J Duras, ... Blood 142, 4485, 2023 | | 2023 |
| Diagnosis to Treatment Interval Is the Most Significant Prognostic Factor Compared to Symptoms to Treatment As Well As to Contact to Treatment Intervals in DLBCL Patients P Vodicka, M Masar, M Klanova, K Benesova, J Koren, P Klener, ... Blood 142, 4510, 2023 | | 2023 |
| DLBCL Patients' Journey: From Symptoms to Diagnosis P Vodicka, M Masar, M Klanova, K Benesova, J Koren, P Klener, ... Blood 142, 3140, 2023 | | 2023 |
| How Relevant Are the Control Cohorts of Clinical Trials in Patients with Newly Diagnosed DLBCL in a Daily Practice? P Vodicka, K Benesova, A Janikova, D Belada, H Mocikova, J Pirnos, ... Blood 140 (Supplement 1), 3775-3776, 2022 | | 2022 |
| HOW TO TREAT ELDERLY PATIENTS OVER 80 YEARS WITH DIFFUSE LARGE B-CELL LYMPHOMA: ALL BENEFIT FROM RITUXIMAB AND SELECTED ONES FROM R-CHOP P VODICKA, A JANIKOVA, A SYKOROVA, V PROCHAZKA, H MOCIKOVA, ... | | |
